Hormonal
At maximum approved doses, tirzepatide (15 mg) produces significantly greater weight loss and glycemic improvement than semaglutide (2.4 mg).
If you are treating obesity with GLP-1/GIP agonists at their maximum FDA-approved doses, Tirzepatide (15 mg) will likely produce more weight loss and better blood sugar control than Semaglutide (2.4 mg). However, cost and availability may make Semaglutide a more practical first choice for some patients.
Tirzepatide demonstrated superiority over semaglutide in percentage weight reduction (mean difference [MD] 6.10%; 95% CI: 3.64, 8.57), absolute weight loss (MD 4.55 kg; 95% CI: 1.28, 7.83), BMI reduction (MD 1.71 kg/m2; 95% CI: 0.08, 3.34), and waist circumference reduction (MD 2.89 cm; 95% CI: 1.25, 4.53).
Why this rating
Network meta-analysis of 28 RCTs with 34,367 participants and high certainty of evidence (GRADE).
Source
Who Wins the Battle Against Obesity? A Network Meta‐Analysis Comparing Tirzepatide and Semaglutide
Júlia Cremonini Bernardi et al. · Journal of Diabetes · 2026
DOI 10.1111/1753-0407.70192
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →